This segment discusses the safety and side effect profiles of intravenous and subcutaneous immunotherapy in advanced melanoma ...
Please provide your email address to receive an email when new articles are posted on . Leqembi Iqlik is the first approved in-home anti-amyloid injectable for early Alzheimer’s disease. Patients ...
Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma (IgG1) monoclonal antibody directed against aggregated soluble (protofibril ...
Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study Patients with ≥1 prior line of therapy were ...
A 20-year-old female presented with a history of psoriasis and psoriatic arthritis since childhood. She started treatment with etanercept (Enbrel ®) 1 month previously. One day after a subcutaneous ...
Ocrelizumab and hyaluronidase is now the first and only twice-yearly subcutaneous injection approved for relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). The ...
LEQEMBI IQLIK is the first and only anti-amyloid treatment to offer an at-home injection to help patients and care partners continue to treat this progressive, relentless disease after initial ...
Nucala (mepolizumab) is a brand-name subcutaneous injection that comes in different forms. Depending on which form you’re prescribed, you or your doctor will administer the injection. Nucala injection ...
Basel, 16 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the United States Food and Drug Administration (U.S. FDA) has approved OCREVUS ZUNOVO™ (ocrelizumab & hyaluronidase-ocsq) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results